Propafenone
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Propafenone: From Cardiac Arrhythmia to Manic Bipolar Affective Disorder
One-Sentence Summary
Propafenone (DrugBank ID DB01182) is a Class IC antiarrhythmic agent; detailed original-indication licensing data was not found in this evidence pack, but the drug is generally known for treating cardiac arrhythmias. The TxGNN model predicts it may be relevant to manic bipolar affective disorder (score 99.80%), but the only supporting literature currently available (3 publications, 0 clinical trials) describes propafenone inducing mania/psychosis as an adverse effect — not treating it. This prediction should be interpreted with caution.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no license records found); propafenone is generally recognized as a Class IC antiarrhythmic per DrugBank identity |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L4 (case-report-level literature only; no RCTs; evidence describes adverse drug reaction risk, not therapeutic benefit) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological identity, propafenone is a Class IC antiarrhythmic that blocks cardiac sodium channels and also has mild beta-adrenergic blocking activity; it is structurally related to the antidepressant bupropion. No original approved-indication text was found in the taiwan_regulatory license records for this dataset (0 licenses, market status “Not Marketed”), so a direct original-vs-new indication comparison cannot be made from the evidence pack itself.
TxGNN scores propafenone very highly (99.80%) for “manic bipolar affective disorder.” However, all three retrieved publications describe the opposite direction of association — propafenone triggering mania or psychosis as an adverse drug reaction, not treating it:
- “A case of mania secondary to propafenone” (1985) speculates this may stem from propafenone’s structural similarity to bupropion, which does have antidepressant/mood-activating activity.
- “An organic psychosis due to a venlafaxine-propafenone interaction” (2001) describes a drug-drug interaction precipitating psychosis in a bipolar patient.
- The 2020 pharmacovigilance review discusses harmful interactions between antipsychotics and cardiovascular drugs (including propafenone) in patients with bipolar disorder/schizophrenia comorbid with cardiovascular disease.
This is a case where a knowledge-graph model may have learned a strong association between propafenone and bipolar/mania concepts purely from co-occurrence in adverse-event literature, without that association reflecting a therapeutic benefit. This distinction is critical before any further evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2579063 | 1985 | Case report | J Clin Psychiatry | Case of mania secondary to propafenone; authors speculate structural similarity to bupropion may confer mood-activating/antidepressant-like activity |
| 11949740 | 2001 | Case report | Int J Psychiatry Med | Organic psychosis triggered by a venlafaxine-propafenone drug interaction in a patient with bipolar affective disorder |
| 32124390 | 2020 | Pharmacovigilance review | Pharmacological Reports | Evaluates harmful drug-drug interactions between antipsychotics and cardiovascular medications (incl. propafenone) in patients with bipolar disorder/schizophrenia and comorbid cardiovascular disease |
Note: None of the above literature supports using propafenone to treat bipolar/manic symptoms; all describe it as a potential trigger or interaction risk for psychiatric adverse effects.
US Market Information
No marketing authorization records were found in this evidence pack. The drug is currently listed as Not Marketed with 0 licenses on file, so no product/dosage-form/indication table can be produced.
Safety Considerations
No structured safety data (key warnings, contraindications, or drug-interaction records) was available in this evidence pack — please refer to the package insert for official safety information.
Additional safety signal identified from literature (not from official safety data sources): Case reports indicate propafenone may precipitate mania or psychosis, particularly in patients with bipolar disorder or in combination with other psychoactive/cardiovascular drugs (e.g., venlafaxine). This should be treated as a caution flag rather than supporting evidence for the predicted indication.
Conclusion and Next Steps
Decision: Hold
Rationale: The only literature evidence available for “manic bipolar affective disorder” describes propafenone-induced mania/psychosis as an adverse reaction, not a therapeutic effect — this contradicts rather than supports the predicted indication. There are no clinical trials, no original-indication data, and no MOA data on file, and the TFDA label/warning data gap is Blocking per the meta data-gap list.
To proceed, the following is needed:
- TFDA (or equivalent) package insert / warnings and contraindications (currently a Blocking data gap, DG001)
- Confirmed mechanism of action from DrugBank (currently a High-severity data gap, DG002)
- Original approved-indication and licensing records for propafenone in this jurisdiction
- Reassessment of whether “manic bipolar affective disorder” should remain a candidate indication, or be reclassified as a safety signal for psychiatric monitoring in current antiarrhythmic use
- Consider separately evaluating rank 2 (catecholaminergic polymorphic ventricular tachycardia), rank 5 (incessant infant ventricular tachycardia), and rank 6 (arrhythmogenic right ventricular cardiomyopathy) — these show literature with actual therapeutic use of propafenone (including a 35-year case of effective CPVT treatment and RyR2-channel-blocking mechanism studies) and are mechanistically consistent with propafenone’s known antiarrhythmic action, making them more promising repurposing candidates than the current top-ranked prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.